Wockhardt gets USFDA’s nod for injection of Decitabine

11 Apr 2019 Evaluate

Wockhardt has received approval from the United States Food & Drug Administration (USFDA) for an ANDA for 50mg injection of Decitabine, which is used to treat certain forms of cancer. Wockhardt's Decitabine Injection is a generic version of Dacogen, marketed in USA and other countries by Otsuka.

Decitabine is used to treat Myelodysplastic syndromes (MDS), a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. According to IQVIA February 2019 data, the product has sales of $120 million in the US.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1445.75 -12.80 (-0.88%)
02-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1878.00
Dr. Reddys Lab 1373.70
Cipla 1537.55
Lupin 2396.30
Zydus Lifesciences 990.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.